Value Based Contracts are becoming increasingly important and commonplace. VBCs also have important implications for Government Pricing programs. Therefore, life sciences companies need to take a coordinated and collaborative approach towards compliance that involves multiple stakeholders to evaluate the agreements and the potential impact on Government Pricing.
Value Based Contracts (“VBCs”) are the talk of the town these days. But for all of the talk there is little substantive information or guidance to help the pharmaceutical manufacturer understand the landscape of VBCs. This includes the potential impact and risks related to Government Program (“GP”) reporting requirements.
Read Full Article in the November 2016 Issue of Life Science Compliance Update